股腘动脉介入术后再狭窄的新型血管造影风险评分
本研究基于前瞻性多中心注册研究1799条肢体,开发了一种血管造影评分用于预测股腘动脉EVT术后12个月再狭窄风险。多变量分析显示远端参考血管直径、病变长度和慢性完全闭塞是独立预测因素,该评分与12个月再狭窄显著独立相关,而TASC分级无此关联。
要点
- 血管造影评分基于远端参考血管直径、病变长度和慢性完全闭塞三个因素构建。
- 该评分与12个月再狭窄风险显著独立相关,而TASC分级无此关联。
- 药物洗脱支架和覆膜支架与较低再狭窄风险独立相关,单纯球囊扩张风险较高。
核心结论
- 血管造影评分与股腘动脉EVT术后12个月再狭窄风险显著独立相关,而TASC分级无此关联。
研究设计与样本
- 前瞻性多中心注册研究,纳入1578例患者共1799条肢体,平均年龄74±9岁,男性1090例。
- 所有患者接受血管内超声支持的股腘动脉EVT,采用多变量分析筛选12个月再狭窄相关因素。
主要发现
- 12个月一期通畅率为65.1%(95%CI 62.7%至67.5%)。
- 远端参考血管直径每增加1mm,再狭窄风险降低(OR 0.71,95%CI 0.62至0.81,p<0.001)。
- 病变长度每增加10cm,再狭窄风险增加(OR 1.39,95%CI 1.19至1.62,p<0.001)。
- 慢性完全闭塞与再狭窄风险增加独立相关(OR 1.56,95%CI 1.15至2.10,p=0.004)。
- 与裸镍钛支架相比,单纯球囊扩张再狭窄风险更高(OR 2.31,95%CI 1.67至3.18,p<0.001),药物洗脱支架(OR 0.65,95%CI 0.43至0.99,p=0.045)和覆膜支架(OR 0.24,95%CI 0.12至0.50,p<0.001)风险更低。
关键数值与推荐
- 血管造影评分由远端参考血管直径、病变长度和慢性完全闭塞三个因素构建,未纳入TASC分级。
临床怎么用
- 该评分可用于识别股腘动脉EVT术后再狭窄高风险患者,辅助决策是否使用紫杉醇洗脱器械。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To present a novel angiographic scoring system that stratifies the risk of restenosis after endovascular therapy (EVT) to inform the decision to use paclitaxel-eluting devices in the femoropopliteal segment. MATERIALS AND METHODS: A prospective, multicenter registry including 1799 limbs of 1578 patients (mean age 74±9 years; 1090 men) with symptomatic peripheral artery disease undergoing intravascular ultrasound-supported femoropopliteal EVT was used as the basis for developing the angiographic score. Multivariable analysis identified baseline patient and limb characteristics associated with restenosis at 12 months. These risk factors for 12-month restenosis were explored using a generalized linear mixed model with a logit-link function in which the inter-institutional and inter-subject variability were treated as random effects. The multiple imputation method was adopted to address missing data. Results of the regression analysis are presented as the odds ratio (OR) with 95% confidence interval (CI). RESULTS: Twelve-month primary patency was estimated to be 65.1% (95% CI 62.7% to 67.5%). After multivariable analysis, distal reference vessel diameter per 1 mm (OR 0.71, 95% CI 0.62 to 0.81, p<0.001), lesion length per 10 cm (OR 1.39, 95% CI 1.19 to 1.62, p<0.001), and chronic total occlusion (OR 1.56, 95% CI 1.15 to 2.10, p=0.004) were independently associated with the 12-month restenosis risk, whereas baseline patient risk factors were not. Compared to bare nitinol stent implantation, plain angioplasty (OR 2.31, 95% CI 1.67 to 3.18, p<0.001) was independently associated with a higher risk of 12-month restenosis, while drug-eluting stents (OR 0.65, 95% CI 0.43 to 0.99, p=0.045) and stent-grafts (OR 0.24, 95% CI 0.12 to 0.50, p<0.001) were independently associated with a lower risk of 12-month restenosis. The angiographic score, which was developed by using the 3 angiographic factors but not the TransAtlantic Society Consensus II (TASC) class, was significantly and independently associated with 12-month restenosis. CONCLUSION: The current study demonstrated a novel angiographic score for 12-month restenosis after femoropopliteal EVT in a real-world clinical practice. The developed score was significantly and independently associated with the 12-month restenosis risk, but the TASC class was not.
引用
- Iida O, Takahara M, Soga Y, et al. A Novel Angiographic Risk Score for Femoropopliteal Interventions. J Endovasc Ther. 2020. PMID: 32813589. doi:10.1177/1526602820948472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。